statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for CRBU
 DateFirmActionFromTo Feb 2022RBC CapitalInitiates Coverage OnOutperform Feb 2022Brookline CapitalInitiates Coverage OnBuy Dec 2021OppenheimerInitiates Coverage OnOutperform...

Cracking The Code: Understanding Analyst Reviews For Caribou Biosciences

RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou...

Attention Biotech Investors - Stocks To Watch

Expert Ratings For Caribou Biosciences

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday.
read more...

Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Paragon 28 (FNA Research Report) and Caribou Biosciences...

Analysts Are Bullish on Top Healthcare Stocks: Paragon 28 (FNA), Caribou Biosciences (CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling...

Caribou Biosciences, Inc. (NASDAQ:CRBU) Sees Large Growth in Short Interest

Caribou Biosciences received IND clearance from FDA for its lupus treatment...

Caribou Biosciences received IND clearance from FDA for its lupus treatment

-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Caribou Biosciences, Inc. (NASDAQ:CRBU  Get Free Report) shares were up 6.5% during trading on Monday . The stock traded as high as $5.59 and last traded at $5.57. Approximately 298,268 shares...

Caribou Biosciences (NASDAQ:CRBU) Trading 6.5% Higher

Investors eyeing a purchase of Caribou Biosciences Inc (CRBU) shares, but tentative about paying the going market price of 5.20/share, might benefit from considering selling puts among the...

Commit To Buy Caribou Biosciences At $2.50, Earn 7% Annualized Using Options

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Watchers	2,419
52-Wk Low	$1.75
52-Wk High	$8.59

Volume	3.73M
52-Wk High	$8.59
52-Wk Low	$1.75

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.46	--	--	N/A
Q1'24	-$0.41	-$0.46	-11.94%	MISSED
Q4'23	-$0.37	-$0.39	-6.11%	MISSED
Q3'23	-$0.42	-$0.12	71.17%	BEAT
Q2'23	-$0.49	-$0.48	3.00%	BEAT

CRBU Caribou Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals